Literature DB >> 11673511

Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-gamma-secreting, CD8(+) CTL in vivo.

Y Wan1, L Lu, J L Bramson, S Baral, Q Zhu, A Pilon, K Dayball.   

Abstract

By using adoptive transfer of Ag-loaded bone marrow-derived dendritic cells (BMDC), we have established an in vivo model of CTL priming. Activation of CTL in these experiments required both CD4(+) T cells and CD154, demonstrating that this model reflects CD4(+) T cell-dependent dendritic cell (DC) licensing. Because IL-12 has been suggested to play an important role in CTL activation by DC, we examined the ability of BMDC to prime CTL in the complete absence of IL-12 using p40-deficient mice. We observed that the absence of IL-12 does not affect the phenotype or allostimulatory function of BMDC after in vitro maturation. Moreover, there was no difference in the ability of Ag-loaded DC to elicit CTL cytotoxicity, whether the Ag was delivered by virus infection or peptide pulsing. Equal frequencies of Ag-specific, IFN-gamma-secreting CD8(+) T cells developed in both wild-type and IL-12-deficient backgrounds. Finally, CTL generated in the IL-12-deficient environment were capable of protecting immunized mice against tumor challenge, demonstrating that these CTL were fully functional, despite the absence of IL-12 during the maturation process in vivo. These results indicate that IL-12 is not critical for the development of IFN-gamma secreting, CD8(+) T cells and that another mechanism must be used by licensed DC to prime and activate CTL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673511     DOI: 10.4049/jimmunol.167.9.5027

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.

Authors:  Timothy P Moran; Joseph E Burgents; Brian Long; Ivana Ferrer; Elizabeth M Jaffee; Roland M Tisch; Robert E Johnston; Jonathan S Serody
Journal:  Vaccine       Date:  2007-07-17       Impact factor: 3.641

3.  Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.

Authors:  Yongxia Wu; David Bastian; Steven Schutt; Hung Nguyen; Jianing Fu; Jessica Heinrichs; Changqing Xia; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-04       Impact factor: 5.742

4.  Involvement of IL-10 in exhaustion of myeloid dendritic cells and rescue by CD40 stimulation.

Authors:  Kiichi Kajino; Ichiro Nakamura; Hiromichi Bamba; Toshihiro Sawai; Kazumasa Ogasawara
Journal:  Immunology       Date:  2006-10-11       Impact factor: 7.397

5.  Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity.

Authors:  Sheng Zhang; Weiyi Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-26       Impact factor: 4.553

6.  Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells.

Authors:  Shuang Geng; Yiwei Zhong; Shuang Wang; Hu Liu; Qiang Zou; Xiaoping Xie; Chaofan Li; Qingling Yu; Zhonghuai He; Bin Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

7.  Prostaglandin E2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells.

Authors:  Philipp Gierlich; Veronika Lex; Antje Technau; Anne Keupp; Lorenz Morper; Amelie Glunz; Hanno Sennholz; Johannes Rachor; Sascha Sauer; Ana Marcu; Götz Ulrich Grigoleit; Matthias Wölfl; Paul G Schlegel; Matthias Eyrich
Journal:  Cancer Immunol Immunother       Date:  2020-02-25       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.